52345-47-8

Basic information

• Product Name: 2-((4-METHYLPHENYL)SULFONYL)ETHANAMIDE
• Synonyms: 2-[(4-methylphenyl)sulfonyl]-acetamid;2-(P-TOLUENESULFONYL)ACETAMIDE;2-((4-METHYLPHENYL)SULFONYL)ETHANAMIDE;2-(4-METHYLPHENYLSULFONYL)ACETAMIDE;2-[(4-methylphenyl)sulphonyl]acetamide;4-Methylphenylsulfonylacetamide
• CAS NO: 52345-47-8
• Molecular Formula: C₉H₁₁NO₃S
• Molecular Weight: 213.25
• EINECS: 257-864-9
• Mol File: 52345-47-8.mol
• Article Data: 2

Chemical Properties

• Melting Point: 167 °C
• Boiling Point: 474.1°C at 760 mmHg
• Flash Point: 240.6°C
• Appearance: /
• Density: 1.3185 (rough estimate)
• Vapor Pressure: 3.7E-09mmHg at 25°C
• Refractive Index: 1.5270 (estimate)
• CAS DataBase Reference: 2-((4-METHYLPHENYL)SULFONYL)ETHANAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-((4-METHYLPHENYL)SULFONYL)ETHANAMIDE(52345-47-8)
• EPA Substance Registry System: 2-((4-METHYLPHENYL)SULFONYL)ETHANAMIDE(52345-47-8)

Safety Data

• Safety Statements: 24/25
• Hazardous Substances Data: 52345-47-8(Hazardous Substances Data)

Usage

General Description

2-((4-Methylphenyl)sulfonyl)ethanamide is a chemical compound with the molecular formula C10H13NO3S. It is an amide derivative of 4-methylbenzenesulfonic acid, and is used as a building block in organic synthesis. 2-((4-METHYLPHENYL)SULFONYL)ETHANAMIDE is a white to off-white solid at room temperature, and is soluble in organic solvents like acetone and ethanol. It is known to have potential applications in medicinal chemistry, such as in the development of pharmaceuticals and biologically active compounds. The compound's sulfonyl group gives it unique reactivity and properties, making it a valuable tool for chemical research and development.

InChI:InChI=1/C9H11NO3S/c1-7-2-4-8(5-3-7)14(12,13)6-9(10)11/h2-5H,6H2,1H3,(H2,10,11)

Upstream product

• 55490-03-4 bromo-(toluene-4-sulfonyl)-acetic acid amide 
• 7732-18-5 water 
• 7803-57-8 hydrazine hydrate 
• 56185-22-9 dibromo-(toluene-4-sulfonyl)-acetic acid amide 
• 10034-85-2 hydrogen iodide 
• 64-19-7 acetic acid 
• 99766-14-0 (p-tolylsulfonyl)acetyl chloride 
• 3937-96-0 tosylacetic acid 
• 5697-44-9 p-tolylsulfonylmethyl isocyanide 
• 459-44-9 4-methylbenzenediazonium tetrafluoroborate 
• 824-79-3 sodium 4-methylbenzenesulfinate 
• 79-07-2 Chloroacetamide 
• 2850-19-3 (toluene-4-sulfonyl)-acetic acid ethyl ester 
• 110-89-4 piperidine 

Downstream Products

• 99972-93-7 4-(toluene-4-sulfonyl)-pyrrolidine-2,3,5-trione 
• 61053-61-0 2-Methanesulfonyl-2-(toluene-4-sulfonyl)-acetamide 
• 55490-03-4 bromo-(toluene-4-sulfonyl)-acetic acid amide 
• 56185-22-9 dibromo-(toluene-4-sulfonyl)-acetic acid amide 
• 54334-58-6 2-(toluene-4-sulfonyl)-thioacetamide 
• 37891-95-5 bromomethyl 4-tolyl sulfone 
• 855881-88-8 dichloro-(toluene-4-sulfonyl)-acetic acid amide 
• 26958-47-4 1,1-Di-methylthio-2-tosylethen 
• 31350-39-7 dibromomethyl-p-tolyl sulfone 
• 41317-66-2 p-Methylphenyl-<2.2-(ethylendithio)vinyl>sulfon 
• 871893-56-0 3-(toluene-4-sulfonyl)-quinolin-2-ol 

Relevant articles and documents

Identification of BR102910 as a selective fibroblast activation protein (FAP) inhibitor

Fibroblast activation protein (FAP) belongs to the family of prolyl-specific serine proteases and displays both exopeptidase and endopeptidase activities. FAP expression is undetectable in most normal adult tissues, but is greatly upregulated in sites of tissue remodeling, which include fibrosis, inflammation and cancer. Due to its restricted expression pattern and dual enzymatic activities, FAP inhibition is investigated as a therapeutic option for several diseases. In the present study, we described the structure–activity relationship of several synthesized compounds against DPPIV and prolyl oligopeptidase (PREP). In particular, BR102910 (compound 24) showed nanomolar potency and high selectivity. Moreover, the in vivo FAP inhibition study of BR102910 (compound 24) using C57BL/6J mice demonstrated exceptional profiles and satisfactory FAP inhibition efficacy. Based on excellent in vitro and in vivo profiles, the potential of BR102910 (compound 24) as a lead candidate for the treatment of type 2 diabetes is considered.